NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Parvus Therapeutics Inc.

Parvus Therapeutics Inc.

Private
South San Francisco, CaliforniaHealthcare & Life Scienceshttps://parvustx.com/

Last Round

Corporate Funding

Mar 20, 2024

Total Funding Raised

$19.7M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Parvus Therapeutics Inc. is a clinical-stage biotechnology company developing proprietary pMHC nanomedicine drug candidates designed to trigger the in vivo generation of antigen-specific regulatory T cells (Tregs) to treat autoimmune diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share

AI Layer

Non-AI

Keywords

nanomedicine platformautoimmune disease treatmentNavacimsimmune toleranceTreg inductionregulatory T cellsTregsantigen-specific immunotherapyclinical-stage biotechTreg therapybiotech licensingtolerogenic therapypMHC nanomedicinesin vivo therapyinflammatory bowel diseaseIBD

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Parvus Therapeutics Inc. Comparables

Compare Parvus Therapeutics Inc. with similar companies based on industry and business-model similarity.

Parvus Therapeutics Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Cour Pharma
86%
Topas Therapeutics
84%
Anokion
83%

Parvus Therapeutics Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Corporate FundingMar 20, 2024
Corporate FundingApr 19, 2017
GrantJul 30, 2009

Key People

Founding team and executive leadership

Peter Strumph

Chief Executive Officer

Executive Team

Parvus Therapeutics Inc. Investors

Notable investors and investment history

Parvus Therapeutics Inc. investors
InvestorRounds
National Research Council Canada Industrial Research Assistance ProgramGrant
Innovate CalgaryAngel

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 18, 2026

    Monthly visitors increased 80% MoM.

  • Jan 19, 2026

    Monthly visitors increased 148% MoM, reaching 1.4K.

Parvus Therapeutics Inc. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Parvus Therapeutics Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Parvus Therapeutics Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersSouth San Francisco, California
Employee Range25
Year Founded2009
Last FundingMar 20, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.